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Abstract Conjugated polymers due to their reversible
transition between the redox states are potentially able to
immobilise and release ionic species. In this study, we have
successfully developed a conducting polymer system based
on poly(3,4-ethylenedioxythiophene) (PEDOT) for elec-
trically triggered, local delivery of an ionic form of ibu-
profen (IBU), a non-steroidal anti-inflammatory, and
analgesic drug. It was shown that by changing the elec-
tropolymerisation conditions, the polymer matrix of spec-
ified IBU content can be synthesised. The electrochemical
synthesis has been optimised to obtain the conducting
matrix with the highest possible drug content. The process
of electrically stimulated drug release has been extensively
studied in terms of the dynamics of the controlled IBU
release under varying conditions. The maximum concen-
tration of the released IBU, 0.66 (±0.10) mM, was
observed at the applied potential E = -0.5 V (vs. Ag/
AgCl). It was demonstrated that the immobilisation-release
procedure can be repeated several times making the PE-
DOT matrix promising materials for controlled drug
release systems applied e.g. in neuroprosthetics.
Introduction
Conjugated polymers are widely known for their electrical
properties and have found numerous applications in areas
such as organic solar cells, organic light-emitting diodes,
supercapacitors, actuators, etc. [1–4]. Nowadays, conduct-
ing polymers have appeared also as materials suitable for
biomedical engineering. For the last decade, numerous
biomedical applications based on biocompatible conducting
polymers have been investigated, i.e. biosensors, molecular
scaffolds, coatings for neuroprosthetics, and drug delivery
systems [5–8]. Conjugated polymers, especially polypyrrole
(PPy) and poly(3,4-ethylenedioxythiophene) (PEDOT), are
now materials that are in a centre of attention for biomedical
engineering; they have been proven to be biocompatible and
may be introduced into a human body without any harmful
effect on health [9–14]. Besides, their ability to conduct
electricity is a significant advantage that enables efficient
ways of processing and opens new potentially commercial
applications, e.g. in neuroprosthetics [15–17]. It is known
that implantable neural electrodes made of metal cause
allergic reactions and inflammation, moreover, the intro-
duction of implants carries the risk of infections [18]. Due to
their biocompatibility, PPy and PEDOT films may act as an
interface between the metal surface of implant and neural
tissue reducing the risk of inflammation and glial scar for-
mation [19–21].
The immobilisation of biologically active molecules in
conjugated polymer matrices may lead to further increase
in polymer biocompatibility [20, 22]. Through an inten-
tional choice of immobilised biomolecule, it is possible to
prevent inflammation (immobilisation of anti-inflammatory
drugs), infection (immobilisation of antibiotics), or brain
oedema (immobilisation of steroid drugs) [23–25]. The
immobilisation of neurotransmitters such as glutamate may
be a step toward the development of retinal prosthesis [26].
The ion-exchangeable properties of intrinsically conduct-
ing polymers make them promising materials for controlled
drug delivery systems. Biologically active compounds,
which typically include ionic bonds in their structure, can
be therefore immobilised in a conducting polymer matrix
and released in a controlled way when stimulated electri-
cally [23, 24].
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Numerous procedures of electrochemical immobilisa-
tion followed by electrically triggered drug release have
been already presented in the literature. Piro et al. [27]
demonstrated the electrochemical method of incorporation
of oligonucleotides into PEDOT films followed by their
release in a simple ion exchange process. Wadhwa et al.
[18] developed PPy matrix for electrically controlled and
local delivery of dexamethasone—a synthetic glucocorti-
coid anti-inflammatory drug. Esrafilzadeh et al. [28] pre-
sented conducting polymer fibres loaded with
ciprofloxacin—an antibiotic that can be released or sus-
tained in response to electrical stimulation. None of them,
however, studied the stability of polymer matrix during
stimulated drug release. This is an important question when
considering medical applications of such matrices and their
implementation into a human body [29–32].
In this study, we have described the synthesis of the
conducting polymer matrix based on PEDOT as an
example of biocompatible, conjugated polymer that
recently has gained much interest in biomedical engineer-
ing [33–36]. The superior chemical and electrochemical
stability is the main advantage of PEDOT compared to
other currently applied conjugated polymers [37]. As a
drug of interest, a-methyl-4-(isobutyl)phenylacetic acid
(ibuprofen, IBU) has been chosen, which is known as a
non-steroidal anti-inflammatory and analgesic drug show-
ing an ability to enhance wound healing [38–40]. The
electrochemical immobilisation of IBU in PEDOT matrix
has been investigated together with the study of electrically
triggered drug release and the examination of the stability
of polymer matrix against applied potential.
Materials and methods
Materials
3,4-Ethylenedioxythiophene (EDOT), lithium perchlorate
of A.C.S. grade and IBU sodium salt (sodium a-methyl-4-
(isobutyl)phenylacetate, IBU, MW = 228.26 g mol-1)
were obtained from Sigma Aldrich. Potassium chloride,
dipotassium phosphate and monopotassium phosphate
were obtained from POCh. All aqueous solutions were
prepared with the use of deionised water.
Instrumentation
Electrochemical measurements and conditioning were
performed in a three-electrode cell by use of CH Instru-
ments 620 electrochemical workstation. The electrochem-
ical synthesis of polymers was performed by means of
cyclic voltammetry; the process of conditioning was car-
ried out potentiostatically. The concentration of released
IBU was monitored by means of Hewlett Packard 8453
UV–Vis Diode Array Spectrophotometer.
One-step synthesis of PEDOT/LiClO4/IBU
A three-electrode electrochemical cell was set up in a 3-ml
electrochemical glass cell with 1 cm2 platinum foil work-
ing electrode, Ag/AgCl as a reference electrode and glassy
carbon rod as an auxiliary electrode. The polymer films
containing IBU (PEDOT/LiClO4/IBU) were obtained by
means of cyclic voltammetry (CV) in aqueous solution
containing 10 mM EDOT, 10 mM IBU, 0.1 M LiClO4,
which was sonicated prior to the experiment for 30 min.
Typical polymer film was formed on Pt electrode within
the potential range of 0–1.1 V (vs. Ag/AgCl) at the scan
rate v = 100 mV s-1 for 25 potential cycles.
Three-step synthesis of PEDOT/LiClO4/IBU
In the three-step synthesis, the same three-electrode elec-
trochemical cell was used as that described in the previous
section. In the first step, the polymer film was obtained
from aqueous solution containing 10 mM EDOT and
0.1 M LiClO4 in the similar procedure employing cyclic
voltammetry with a narrower potential range of 0–1.0 V
(vs. Ag/AgCl), scan rate v = 100 mV s-1, and number of
potential cycles equal to 50.
In the second step, the original ClO4
- dopant was
removed from the polymer matrix by conditioning it at a
reduction potential Ered = -0.7 V (vs. Ag/AgCl) for
10 min in 0.1 M LiClO4 aqueous solution. The IBU
immobilisation occurred in the third step, when the poly-
mer matrix after rinsing with deionised water was oxidised
at a potential Eox = 0.8 V (vs. Ag/AgCl) in 0.4 M IBU
aqueous solution for 10 min.
Release of IBU from PEDOT/LiClO4/IBU matrix
The concentration of IBU released from PEDOT/LiClO4/
IBU matrix was determined using UV–Vis spectroscopic
measurements under potentiostatic conditions. The three-
electrode electrochemical cell was set up in a 2-mm quartz
cuvette, in which the PEDOT/LiClO4/IBU-modified plati-
num-working electrode was mounted together with Ag
wire used as a pseudoreference electrode, and graphite rod
as an auxiliary electrode. Before measurements, the elec-
trode covered with PEDOT/LiClO4/IBU was soaked in
PBS solution for 10 min to wash off any loosely attached
IBU and unreacted monomer. In order to release IBU from
PEDOT/LiClO4/IBU matrix, a constant potential in the
range -0.8 to 0.8 V (vs. Ag/AgCl) was stepped for a
specified period of time. After each period of time at the
given potential, the UV–Vis spectra were recorded for IBU
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released to the solution. All these measurements of the
controlled release of the immobilised IBU were performed
in the pH 6.5 phosphate buffer solution, PBS, containing
0.15 M KCl, 0.006 M K2HPO4, 0.001 M KH2PO4.
Stability of PEDOT/LiClO4/IBU matrix at variable
potential
The stability of PEDOT/LiClO4/IBU matrix exposed to a
given electrode potential was determined in terms of the
charge storage capacity, CSC, of the matrix. That factor
was calculated as the electric charge integrated under





where t1 is the beginning of CV cycle, t2 is the end of CV
cycle.
The CVs were recorded for the modified platinum
electrode in PBS after 20 min exposition to a given
potential.
Results and discussion
One-step synthesis of PEDOT/LiClO4/IBU
As many other anions, IBU in its ionic form (Scheme 1) is
able to participate in the polymer doping process, which is
a part of the electropolymerisation reaction. Molecules like
EDOT when oxidised (chemically or electrochemically)
extend their conjugated bonding system, forming positively
charged polymer chain that is stabilised by doping of
anions from the reaction environment. Under the electro-
chemical conditions, the polymerisation/doping process
occurs at positive potentials applied to the electrode in the
electrolyte solution containing monomer. Thus, a presence
of IBU- in the electrolyte solution may lead to its immo-
bilisation in the polymer matrix, which is created on the
electrode surface. This process is shown in Scheme 2.
The current versus potential curves recorded in subsequent
scans make it possible to observe the progress of electropoly-
merisation process, as shown in Fig. 1. Two sets of CV curves
were collected, the first for the solution containing EDOT,
LiClO4 and IBU (Fig. 1a) and the second for the case, when
IBU was not present in the solution (Fig. 1b). In both cases, the
increase of current indicates that the monomer is irreversibly
oxidised near 1.1 V (vs. Ag/AgCl). Also for both data sets, the
gradually increasing currents confirm formation of conductive
deposits, typical for the electropolymerisation process. At the
same number of potential scans, the final level of the resulting
currents and corresponding electric charge are evidently dif-
ferent, indicating a slower process of electrochemical poly-
merisation of EDOT in case of IBU presence in solution
Scheme 1 The chemical structure of anionic form of IBU
Scheme 2 The schematic representation of the immobilisation of
IBU into PEDOT matrix during the process of electropolymerisation
Fig. 1 The CV curves recorded during electrochemical polymerisa-
tion of 10 mM EDOT in 0.1 M LiClO4 aqueous solution in the
presence of 10 mM IBU (a), and without IBU (b); potential range
0–1.1 V (vs. Ag/AgCl), scan rate v = 100 mV/s, 25 potential cycles
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(Fig. 1a). This may be due to the fact that the molecule of IBU
is significantly larger than the molecule of electrolyte, thus the
incorporation of drug into the structure of the polymer is less
spatially favourable. The preliminary results indicated that the
molar ratio of EDOT to IBU equal to 1:1 produces a polymer
with the highest drug content, approximately 60 lg cm-2
(mass of IBU immobilised in the unit surface area of Pt elec-
trode). The charge storage capacity, CSC, calculated for PE-
DOT/LiClO4/IBU (22.3 mC) was however not as large as for
PEDOT/LiClO4 film (43.6 mC) polymerised under analogous
conditions as indicate the CV curves shown in Fig. 2. The CSC
factor used in here is simply current integrated along the
potential axis recorded for the polymer-coated electrode placed
in the pure electrolyte solution. It was found that the use of
higher IBU concentrations suppresses the formation of poly-
mer film, therefore it has adverse effects on its charge storage
capacity. When IBU was present at lower concentration in the
monomer solution (1, 2, or 5 mM), the amount of IBU im-
mobilised in the polymer film was as low as 5, 6 and
11 lg cm-2, respectively.
Three-step synthesis of PEDOT/LiClO4/IBU
The three-step synthesis of PEDOT/LiClO4/IBU matrix
allows to separate the processes of electropolymerisation
and immobilisation. In this procedure, the polymer film is
formed in pure electrolyte solution, thus it is doped only
with perchlorate ions. Electrochemical reduction of the
film eliminates to some extent that dopant from the poly-
mer. Oxidation of the polymer is then carried out in the
aqueous solution of IBU only. The CVs recorded on Pt
electrodes modified with PEDOT/LiClO4 and PEDOT/
LiClO4/IBU obtained via one-step (1) and three-step (3)
procedures are compared in Fig. 2. The average current
magnitude of PEDOT/LiClO4/IBU(3) is larger than for
PEDOT/LiClO4/IBU(1) and only slightly smaller than that
for PEDOT/LiClO4. Hence, it may be concluded that a
three-step synthesis route results in a matrix with a higher
CSC (40.9 mC) than matrix synthesised according to the
one-step procedure (22.3 mC), only slightly smaller than
CSC of PEDOT/LiClO4 film (43.6 mC).
Release of IBU from PEDOT/LiClO4/IBU
During the synthesis, anionic compounds are immobilised
in a positively charged conducting polymer matrix to
maintain a neutral charge of the polymer backbone. When
the sufficiently negative voltage is applied to the matrix,
the anionic dopant becomes unnecessary, therefore it is
released to the solution. The schematic representation of
the electrically triggered drug release from conducting
polymer matrix is shown in Scheme 3.
The process of IBU release from PEDOT/LiClO4/IBU
matrix was monitored under potentiostatic conditions using
UV–Vis spectroscopy. Calibration curve was plotted for
absorbance versus IBU concentration (where y is the absor-
bance and x is the IBU concentration in mM). A linear rela-
tionship was observed between 0.01 and 1 mM IBU
concentration satisfying the equation y = 0.0176x ? 1.9365
(R2 = 0.9992).
In order to release IBU from PEDOT/LiClO4/IBU
matrix, a constant potential in the range between -0.8 and
0.8 V (vs. Ag/AgCl) was applied to the matrix placed in
the cuvette. The absorbance at k = 222 nm, which is
characteristic for IBU, was recorded versus time at a given
potential. The changes of absorbance spectra in time for the
matrix stimulated with E = -0.5 V (vs. Ag/AgCl) are
presented in Fig. 3.
The time profiles of IBU release from the matrix stim-
ulated with E = -0.5 V (vs. Ag/AgCl) and matrix main-
tained under open circuit conditions are presented in Fig. 4.
As it can be seen, for the non-stimulated matrix (open
circuit potential), IBU was released in small concentration,
six times lower than for the matrix stimulated with the
reducing potential Ered = -0.5 V (vs. Ag/AgCl). This
result evidently confirms the effect of the applied potential
Scheme 3 The schematic representation of electrically triggered
drug release from PEDOT/LiClO4/IBU matrix
Fig. 2 The CVs recorded on PEDOT/LiClO4 (red line) and PEDOT/
LiClO4/IBU working electrodes synthesised in one-step (1) (green
line and dots) and three-step(3) (blue dotted line) procedure, and CV
recorded on bare Pt-working electrode in 0.1 M LiClO4 solution (grey
dots); scan rate v = 100 mV/s
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on the process of the drug release. The greatest quantity of
IBU appears to be released during the first 2 min of the
electric stimulation, as compared to longer times. It sug-
gests that only a small portion of IBU molecules is
imbedded deeply within the polymeric structure of the
matrix; also the process of full reduction of PEDOT is
practically completed within the applied stimulation time.
Under the described conditions, a total time below 10 min
is required to reach equilibrium (tequil) in the system, then
the solution concentration of IBU is stable.
Since the ratio of the amounts of oxidised and reduced
forms of the conjugated polymer is strictly determined by
the potential applied to the polymer film, therefore one can
expect variation in the concentration of IBU released to the
solution as a function of the value of stimulating potential.
These data were collected for tequil = 10 min for polymer
films of approximately the same amount of immobilised
IBU. The resulting concentration of IBU released as a
function of applied potential is shown in Fig. 5. The
maximum concentration of IBU released, 0.66 (±0.10)
mM, was observed when the potential E = -0.5 V (vs.
Ag/AgCl) was applied. When PEDOT/LiClO4/IBU was
subjected to more negative potentials, the concentration of
released IBU decreased. This is caused by the effect of
n-doping of negatively charged polymer matrix with cat-
ions present in PBS solution: the incorporation of potas-
sium cations occurs instead of the release of the anionic
form of IBU. The concentration of IBU released decreases
as the value of applied potential increases since the posi-
tively charged film holds the anionic drug; the concentra-
tion of IBU released at E = 0.8 V (vs. Ag/AgCl) was 0.21
(±0.05) mM, which is one-third of the concentration
released at E = -0.5 V (vs. Ag/AgCl). These results are
consistent with the mentioned above effects of the applied
potential on the redox state of conjugated polymer. The
application of negative potentials results in facilitated
release of anionic co-dopant, IBU, while the application of
positive potential results in the drug retention.
The capacity of the polymer matrix towards the amount
of immobilised IBU generally depends on the amount of
polymer; the last in turn is easy to control in the process of
electropolymerisation by variation of the number of CV
cycles. The relation between the drug capacity of the
matrix and the conditions of electrochemical polymerisa-
tion, in terms of number of CV cycles, is presented in
Fig. 6. The data indicate nearly linear relation between the
Fig. 3 The change of absorbance spectra in time for IBU released
from the matrix stimulated with E = -0.5 V (vs. Ag/AgCl)
Fig. 4 The concentration of the released IBU calculated from UV–
Vis data as a function of time of the electric stimulation of PEDOT/
LiClO4/IBU matrices with potential E = -0.5 V (black square) and
under open circuit conditions (red circle). The plain line is only a
visual guide
Fig. 5 The concentration of IBU released as a function of the
potential applied to PEDOT/LiClO4/IBU matrix; the plain line is only
a visual guide. The error bars represent standard deviations for five
independent measurements
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electropolymerisation time and the drug capacity; the first
is represented by the number of CV scans, whereas the
other is expressed in terms of the concentration of released
IBU. These results demonstrate that it is possible to syn-
thesise PEDOT/LiClO4/IBU matrix of a specified IBU
content that can be further effectively released.
Since the three-step synthesis of PEDOT/LiClO4/IBU
allows to separate the processes of electropolymerisation
and immobilisation, it should be possible to apply the
immobilisation-release procedure several times for the
same matrix. Again, the curves representing the concen-
tration of IBU released versus time were plotted for the
PEDOT/LiClO4/IBU matrix that was subjected to four
consecutive immobilisation-release cycles. The plot of the
concentration of released IBU calculated from the corre-
sponding UV–Vis data is shown in Fig. 7. After the first
cycle, the concentration of released IBU was equal to 0.70
(±0.05) mM, whereas each subsequent immobilisation/
release cycle appeared to be less efficient; in the forth cycle
the concentration of IBU released was reduced to 0.34
(±0.02) mM. The observed effect is caused by the gradual
degradation of PEDOT/LiClO4/IBU matrix that usually
occurs when the polymer is exposed to oxidative potential
exceeding its optimal value (overoxidation). If, however,
the potential is carefully chosen, the polymer degradation
during its destructive oxidation can be optimised. On the
other side, the matrix exposed to negative potentials for
longer times (or at no potential applied) keeps its CSC
factor practically unchanged.
The gradual loss of the matrix loading effectiveness, as
observed in the spectral measurements, is likely caused by
a degradation of the polymer film. The CV curves recorded
after each IBU load/release cycle reveal decreasing electric
charge. These data shown in terms of CSC values (Table 1)
are consistent with the spectral results, which all together
give a proof of a limited durability of the PEDOT matrix
when multiple IBU- loadings are attempted.
Conclusions
In this study, a PEDOT-based conducting polymer system
for electrically triggered delivery of an ionic form of IBU has
been developed. The most favourable electropolymerisation
conditions for achieving good electrochemical properties
along with the highest drug content have been found and the
process of electrically stimulated drug release has been
extensively studied. The time profiles have provided the
Fig. 6 The concentration of IBU released versus stimulation time of
polymer matrix for different film thicknesses measured as electro-
polymerisation number of CV cycles: 25 CV cycles (black triangle),
50 CV cycles (blue square), 100 CV cycles (red circle). PEDOT/
LiClO4/IBU matrices were electrically stimulated at potential E =
-0.5 V (vs. Ag/AgCl). The plain line is only a visual guide
Fig. 7 The concentration of IBU released versus time for PEDOT/
LiClO4/IBU matrix subjected to four immobilisation-release cycles:
first cycle (red circle), second cycle (green triangle), third cycle (blue
inverted triangle), forth cycle (pink diamond). The plain line is only a
visual guide
Table 1 The charge storage capacity (CSC) of PEDOT/LiClO4/IBU
matrix calculated from CV data before and after the first, second, third
and forth immobilisation-release cycle as compared to CSC of bare Pt
electrode
Type of surface CSC (mC)
Bare Pt 3.77
Modified Pt before 1st load/release cycle 53.26
Modified Pt after 1st load/release cycle 39.48
Modified Pt after 2nd load/release cycle 25.00
Modified Pt after 3rd load/release cycle 15.53
Modified Pt after 4th load/release cycle 8.93
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information about the dynamics of drug release, while
application of different potentials has shown that the process
of the drug release may be effectively controlled. The con-
centration of the released IBU has been shown to be
dependent on the redox state of the polymer matrix, therefore
application of negative potential resulted in the drug release,
while the positive potentials resulted in the drug retention.
The proposed three-step synthesis of PEDOT/LiClO4/
IBU matrix allowed the separation of the electropolymer-
isation and immobilisation processes, which provided the
matrix of a superior charge storage capacity. It was dem-
onstrated that the immobilisation-release procedure can be
repeated several times making the drug delivery system
able to be reloaded. However, decreasing electric charge
and gradual loss of the matrix loading efficiency after each
IBU load/release cycle show the limited durability of the
PEDOT matrix when multiple IBU-loadings are attempted.
That is why further research should be focused on the
optimisation of the loading-reloading conditions, especially
on the careful choice of the oxidation and reduction
potentials. If, however, the aforementioned conditions are
optimised and the durability of PEDOT is improved, the
PEDOT/LiClO4/IBU system is expected to find application
as a novel carrier for controlled-release local delivery of
anti-inflammatory drug for biomedical engineering.
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